Alex Thompson
Stock Analyst at Stifel
(3.00)
# 1,503
Out of 5,090 analysts
38
Total ratings
63.33%
Success rate
6.41%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alex Thompson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANAB AnaptysBio | Maintains: Buy | $55 → $80 | $44.41 | +80.14% | 1 | Oct 29, 2025 | |
| DNTH Dianthus Therapeutics | Maintains: Buy | $52 → $65 | $44.26 | +46.86% | 2 | Sep 12, 2025 | |
| TVTX Travere Therapeutics | Maintains: Hold | $20 → $25 | $35.00 | -28.57% | 4 | Sep 12, 2025 | |
| ASND Ascendis Pharma | Maintains: Buy | $212 → $254 | $205.44 | +23.64% | 3 | Aug 8, 2025 | |
| CGEM Cullinan Therapeutics | Reinstates: Buy | $22 | $10.59 | +107.74% | 1 | Jun 11, 2025 | |
| KYMR Kymera Therapeutics | Reinstates: Buy | $55 | $66.62 | -17.44% | 1 | May 20, 2025 | |
| AVTX Avalo Therapeutics | Initiates: Buy | $36 | $17.56 | +105.01% | 1 | Mar 25, 2025 | |
| CRNX Crinetics Pharmaceuticals | Initiates: Buy | $60 | $46.67 | +28.56% | 1 | Mar 25, 2025 | |
| ORKA Oruka Therapeutics | Initiates: Buy | $49 | $30.84 | +58.88% | 1 | Oct 11, 2024 | |
| ARGX argenx SE | Maintains: Buy | $485 → $500 | $901.17 | -44.52% | 4 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $36 → $54 | $33.45 | +61.43% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $6 → $2 | $8.72 | -77.06% | 5 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $69 | $14.90 | +363.09% | 2 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $2 → $1 | $2.92 | -65.75% | 4 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $32.02 | +24.92% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $320 | $34.47 | +828.48% | 1 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $34 | $22.84 | +48.86% | 2 | Jul 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33 | $1.21 | +2,627.27% | 1 | Dec 14, 2022 |
AnaptysBio
Oct 29, 2025
Maintains: Buy
Price Target: $55 → $80
Current: $44.41
Upside: +80.14%
Dianthus Therapeutics
Sep 12, 2025
Maintains: Buy
Price Target: $52 → $65
Current: $44.26
Upside: +46.86%
Travere Therapeutics
Sep 12, 2025
Maintains: Hold
Price Target: $20 → $25
Current: $35.00
Upside: -28.57%
Ascendis Pharma
Aug 8, 2025
Maintains: Buy
Price Target: $212 → $254
Current: $205.44
Upside: +23.64%
Cullinan Therapeutics
Jun 11, 2025
Reinstates: Buy
Price Target: $22
Current: $10.59
Upside: +107.74%
Kymera Therapeutics
May 20, 2025
Reinstates: Buy
Price Target: $55
Current: $66.62
Upside: -17.44%
Avalo Therapeutics
Mar 25, 2025
Initiates: Buy
Price Target: $36
Current: $17.56
Upside: +105.01%
Crinetics Pharmaceuticals
Mar 25, 2025
Initiates: Buy
Price Target: $60
Current: $46.67
Upside: +28.56%
Oruka Therapeutics
Oct 11, 2024
Initiates: Buy
Price Target: $49
Current: $30.84
Upside: +58.88%
argenx SE
Jun 24, 2024
Maintains: Buy
Price Target: $485 → $500
Current: $901.17
Upside: -44.52%
Mar 26, 2024
Reiterates: Buy
Price Target: $36 → $54
Current: $33.45
Upside: +61.43%
Dec 18, 2023
Maintains: Hold
Price Target: $6 → $2
Current: $8.72
Upside: -77.06%
Dec 18, 2023
Maintains: Buy
Price Target: $66 → $69
Current: $14.90
Upside: +363.09%
Dec 18, 2023
Maintains: Hold
Price Target: $2 → $1
Current: $2.92
Upside: -65.75%
Sep 13, 2023
Reiterates: Buy
Price Target: $40
Current: $32.02
Upside: +24.92%
Aug 9, 2023
Initiates: Buy
Price Target: $320
Current: $34.47
Upside: +828.48%
Jul 18, 2023
Maintains: Buy
Price Target: $28 → $34
Current: $22.84
Upside: +48.86%
Dec 14, 2022
Initiates: Buy
Price Target: $33
Current: $1.21
Upside: +2,627.27%